CA3143112A1 - Succinate prodrug, compositions containing the succinate prodrug and uses thereof - Google Patents

Succinate prodrug, compositions containing the succinate prodrug and uses thereof Download PDF

Info

Publication number
CA3143112A1
CA3143112A1 CA3143112A CA3143112A CA3143112A1 CA 3143112 A1 CA3143112 A1 CA 3143112A1 CA 3143112 A CA3143112 A CA 3143112A CA 3143112 A CA3143112 A CA 3143112A CA 3143112 A1 CA3143112 A1 CA 3143112A1
Authority
CA
Canada
Prior art keywords
compound
isolated compound
complex
mitochondrial
isolated
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3143112A
Other languages
English (en)
French (fr)
Inventor
Magnus Joakim HANSSON
Alvar Gronberg
Mats Eskil Elmer
Mark Richard FARMERY
Steven James Moss
Lee Robert WEBSTER
Matthew Alan Gregory
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Abliva AB
Original Assignee
Abliva AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abliva AB filed Critical Abliva AB
Publication of CA3143112A1 publication Critical patent/CA3143112A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C327/00—Thiocarboxylic acids
    • C07C327/20—Esters of monothiocarboxylic acids
    • C07C327/30—Esters of monothiocarboxylic acids having sulfur atoms of esterified thiocarboxyl groups bound to carbon atoms of hydrocarbon radicals substituted by nitrogen atoms, not being part of nitro or nitroso groups
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/265—Esters, e.g. nitroglycerine, selenocyanates of carbonic, thiocarbonic, or thiocarboxylic acids, e.g. thioacetic acid, xanthogenic acid, trithiocarbonic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/46—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing sulfur
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/08—Anti-ageing preparations
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Psychology (AREA)
  • Birds (AREA)
  • Cardiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Dermatology (AREA)
  • Gerontology & Geriatric Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Cosmetics (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
CA3143112A 2019-06-19 2020-06-18 Succinate prodrug, compositions containing the succinate prodrug and uses thereof Pending CA3143112A1 (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
DKPA201970382 2019-06-19
DKPA201970383 2019-06-19
DKPA201970382 2019-06-19
DKPA201970384 2019-06-19
DKPA201970383 2019-06-19
DKPA201970384 2019-06-19
PCT/EP2020/066923 WO2020254484A1 (en) 2019-06-19 2020-06-18 Succinate prodrug, compositions containing the succinate prodrug and uses thereof

Publications (1)

Publication Number Publication Date
CA3143112A1 true CA3143112A1 (en) 2020-12-24

Family

ID=71130953

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3143112A Pending CA3143112A1 (en) 2019-06-19 2020-06-18 Succinate prodrug, compositions containing the succinate prodrug and uses thereof

Country Status (11)

Country Link
US (2) US11565998B2 (https=)
EP (2) EP4360708A3 (https=)
JP (2) JP7699551B2 (https=)
KR (1) KR102871719B1 (https=)
CN (1) CN113993842B (https=)
AU (1) AU2020298031B2 (https=)
CA (1) CA3143112A1 (https=)
IL (1) IL288990B2 (https=)
MA (1) MA56506A (https=)
MX (1) MX2021015137A (https=)
WO (1) WO2020254484A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL288990B2 (en) * 2019-06-19 2025-09-01 Abliva Ab Succinate drug meters, preparations containing the succinate drug meters and its uses

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9612331D0 (en) 1996-06-13 1996-08-14 Leo Pharm Prod Ltd Chemical compounds
AUPR059400A0 (en) 2000-10-06 2000-11-02 Bar-Ilan University Formaldehyde-releasing prodrugs
PL3129016T3 (pl) 2014-04-08 2018-10-31 Neurovive Pharmaceutical Ab Nowe przepuszczalne dla komórek związki bursztynianu
SG11201607908QA (en) * 2014-04-08 2016-10-28 Neurovive Pharmaceutical Ab Succinate prodrugs for use in the treatment of lactic acidosis or drug-induced side-effects due to complex i-related impairment of mitochondrial oxidative phosphorylation
IL288990B2 (en) * 2019-06-19 2025-09-01 Abliva Ab Succinate drug meters, preparations containing the succinate drug meters and its uses

Also Published As

Publication number Publication date
EP3986862A1 (en) 2022-04-27
IL288990A (en) 2022-02-01
EP3986862C0 (en) 2024-01-24
US20230033294A1 (en) 2023-02-02
WO2020254484A1 (en) 2020-12-24
EP4360708A3 (en) 2024-12-25
JP7827801B2 (ja) 2026-03-10
US12162824B2 (en) 2024-12-10
JP2022538009A (ja) 2022-08-31
AU2020298031B2 (en) 2025-12-18
BR112021024510A2 (pt) 2022-01-18
US20220162162A1 (en) 2022-05-26
KR20220024780A (ko) 2022-03-03
EP3986862B1 (en) 2024-01-24
JP2025004155A (ja) 2025-01-14
MA56506A (fr) 2022-04-27
AU2020298031A1 (en) 2022-02-03
KR102871719B1 (ko) 2025-10-15
IL288990B2 (en) 2025-09-01
JP7699551B2 (ja) 2025-06-27
US11565998B2 (en) 2023-01-31
EP4360708A2 (en) 2024-05-01
IL288990B1 (en) 2025-05-01
CN113993842A (zh) 2022-01-28
CN113993842B (zh) 2024-07-16
MX2021015137A (es) 2022-01-18

Similar Documents

Publication Publication Date Title
US9439915B2 (en) Activated nitric oxide donors and methods of making and using thereof
KR102643707B1 (ko) Mtorc 조절제 및 이의 용도
WO2007121188A2 (en) Compositions and methods of using r(+) pramipexole
KR20210070978A (ko) 화합물 및 이의 용도
JP7827801B2 (ja) コハク酸プロドラッグ、コハク酸プロドラッグを含有する組成物、及びその使用
JP2024091930A (ja) ｄ－アンフェタミン化合物、組成物、ならびにそれを作製および使用するためのプロセス
HK40110815A (en) Succinate prodrug, compositions containing the succinate prodrug and uses thereof
HK40072910B (en) Succinate prodrug, compositions containing the succinate prodrug and uses thereof
HK40072910A (en) Succinate prodrug, compositions containing the succinate prodrug and uses thereof
WO2017060400A1 (en) Protected carboxylic acid-based metabolites for the treatment of disesases related to mitochondrial dysfunctions
US20220273756A1 (en) Compounds and methods for inhibiting protozoan parasites
KR20210076041A (ko) 레베르 유전성 시신경병증의 치료 및 예방을 위한 조성물 및 방법
BR112021024510B1 (pt) 3-[(2-acetilaminoetiltio)carbonil]propionato de metila isolado, cosmecêutico, nutricosméticos, bebida energética, e, composição farmacêutica
EA045539B1 (ru) Сукцинатное пролекарство, композиции, содержащие сукцинатное пролекарство, и их применение
WO2017060418A1 (en) Protected carboxylic acid-based metabolites for the treatment of mitochondria-related diseases
US20240009164A1 (en) Methods and compounds for treating ulcerative colitis
US11958857B1 (en) 5-(1H-indol-3-yl)-1,3-substitutedpyrimido[4,5-d]pyrimidine-2,4,7(1H,3H,8H)-trione as anticancer agents
CN112739352B (zh) 活化amp-活化的蛋白激酶的化合物及其用途
JP2010500387A (ja) 結晶形態のエポチロンｂおよび医薬組成物における使用
US20260034115A1 (en) Yap1 inhibitors
CN105037490B (zh) 一类乙二醛酶i不可逆抑制剂及其制备方法和用途
CN116850187A (zh) Hapalindole在制备抑制肝癌或乳腺癌的药物中的应用
TW201138768A (en) Valsartan derivatives carrying NO donors for the treatment of vascular and metabolic diseases
CN103037842A (zh) 新颖的药物化合物

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20240318

D15 Examination report completed

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT

Effective date: 20250321

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 5TH ANNIV.) - STANDARD

Year of fee payment: 5

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250610

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250610

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION

Effective date: 20250716

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20250717

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT

Effective date: 20250723

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED

Effective date: 20250723

D00 Search and/or examination requested or commenced

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D00-D149 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S INTERVIEW

Effective date: 20260327

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - VOLUNTARY AMENDMENT

Effective date: 20260408

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT

Effective date: 20260414

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED

Effective date: 20260414

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20260414